Cholecystokinin is necessary for the expression of morphine conditioned place preference

Pharmacology Biochemistry and Behavior

Volumn 85, Issue 4, 2006, Pages 787-795

  Mitchell, Jennifer M ^a,b,c   Bergren, Lindsey J ^c   Chen, Katherine S ^c   Fields, Howard L ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN FRANCISCO   (United States)

Author keywords

Accumbens; Craving; Dopamine; Drug seeking; Incentive; Reward

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; CHOLECYSTOKININ; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; DOPAMINE 2 RECEPTOR; LORGLUMIDE; MORPHINE; RACLOPRIDE; TETRAGASTRIN;

ANIMAL EXPERIMENT; ARTICLE; CONDITIONING; DOPAMINERGIC ACTIVITY; DRUG ABUSE; DRUG EFFECT; MALE; MICROINJECTION; NONHUMAN; NUCLEUS ACCUMBENS; PLACE PREFERENCE; PRIORITY JOURNAL; RAT; REWARD; WITHDRAWAL SYNDROME;

ANIMALS; BENZODIAZEPINONES; CHOLECYSTOKININ; CONDITIONING, OPERANT; MALE; MORPHINE; MORPHINE DEPENDENCE; NUCLEUS ACCUMBENS; PHENYLUREA COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, DOPAMINE D2;

EID: 33846441622     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2006.11.014     Document Type: Article

References (78)

1. Adamec R.E., Shallow T., and Budgell J. Blockade of CCK(B) but not CCK(A) receptors before and after the stress of predator exposure prevents lasting increases in anxiety-like behavior: implications for anxiety associated with posttraumatic stress disorder. Behav Neurosci 111 2 (1997) 435-449
2. Agnati L.F., Celani M.F., and Fuxe K. Cholecystokinin peptides in vitro modulate the characteristics of the striatal 3H-N-propylnorapomorphine sites. Acta Physiol Scand 118 1 (1983) 79-81
3. Baber N.S., Dourish C.T., and Hill D.R. The role of CCK caerulein, and CCK antagonists in nociception. Pain 3 (1989) 307-328
4. Bertoni M., Olivieri F., Manghetti M., Boccolini E., Bellomini M.G., Blandizzi C., et al. Effects of a bicarbonate-alkaline mineral water on gastric functions and functional dyspepsia: a preclinical and clinical study. Pharmacol Res 46 6 (2002) 525-531
5. Bhatnagar S., Viau V., Chu A., Soriano L., Meijer O.C., and Dallman M.F. A cholecystokinin-mediated pathway to the paraventricular thalamus is recruited in chronically stressed rats and regulates hypothalamic-pituitary-adrenal function. J Neurosci 20 14 (2000) 5564-5573
6. Blevins J.E., Stanley B.G., and Reidelberger R.D. Brain regions where cholecystokinin suppresses feeding in rats. Brain Res 860 1-2 (2000) 1-10
7. Bradwejn J., Koszycki D., Couetoux du Tertre A., van Megen H., den Boer J., and Westenberg H. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry 51 6 (1994) 486-493
8. Brog J.S., Salyapongse A., Deutch A.Y., and Zahm D.S. The patterns of afferent innervation of the core and shell in the "accumbens" part of the rat ventral striatum: immunohistochemical detection of retrogradely transported fluoro-gold. J Comp Neurol 338 2 (1993) 255-278
9. Crawley J.N. Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway. J Neurosci 12 9 (1992) 3380-3391
10. Crawley J.N., and Corwin R.L. Biological actions of cholecystokinin. Peptides 15 4 (1994) 731-755
11. Crespi F. The role of cholecystokinin (CCK), CCK-A or CCK-B receptor antagonists in the spontaneous preference for drugs of abuse (alcohol or cocaine) in naive rats. Methods Find Exp Clin Pharmacol 20 8 (1998) 679-697
12. Derrien M., Durieux C., Dauge V., and Roques B.P. Involvement of D2 dopaminergic receptors in the emotional and motivational responses induced by injection of CCK-8 in the posterior part of the rat nucleus accumbens. Brain Res 617 2 (1993) 181-188
13. Derrien M., Dauge V., Blommaert A., and Roques B.P. The selective CCK-B agonist, BC 264, impairs socially reinforced memory in the three-panel runway test in rats. Behav Brain Res 65 2 (1994) 139-146
14. Dourish C.T., Hawley D., and Iversen S.D. Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364,718. Eur J Pharmacol 147 3 (1988) 469-472
15. Dugast C., Brun P., Sotty F., Renaud B., and Suaud-Chagny M.F. On the involvement of a tonic dopamine D2-autoinhibition in the regulation of pulse-to-pulse-evoked dopamine release in the rat striatum in vivo. Naunyn Schmiedebergs Arch Pharmacol 355 6 (1997) 716-719
16. Faris P.L., Komisaruk B.R., Watkins L.R., and Mayer D.J. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 219 4582 (1983) 310-312
17. Ferraro L., O'Connor W.T., Li X.M., Rimondini R., Beani L., Ungerstedt U., et al. Evidence for a differential cholecystokinin-B and-A receptor regulation of GABA release in the rat nucleus accumbens mediated via dopaminergic and cholinergic mechanisms. Neuroscience 73 4 (1996) 941-950
18. Gerhardt P., Voits M., Fink H., and Huston J.P. Evidence for mnemotropic action of cholecystokinin fragments Boc-CCK-4 and CCK-8S. Peptides 15 4 (1994) 689-697
19. Grasing K., Murphy M.G., Lin J., Swigar M., Freedholm D., Clarke L., Zhang J., Wolkowitz O.M., Weingartner H., Putnam K., and Seibold J.R. Human pharmacokinetics and tolerability of L-365,260, a novel cholecystokinin-B antagonist. J Clin Pharmacol 36 4 (1996) 292-300
20. Hamilton M.E., Redondo J.L., and Freeman A.S. Overflow of dopamine and cholecystokinin in rat nucleus accumbens in response to acute drug administration. Synapse 38 3 (2000) 238-242
21. Higgins G.A., Nguyen P., and Sellers E.M. Morphine place conditioning is differentially affected by CCKA and CCKB receptor antagonists. Brain Res 572 1-2 (1992) 208-215
22. Hökfelt T., Skirboll L., Rehfeld J.F., Goldstein M., Markey K., and Dann O. A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: evidence from immunohistochemistry combined with retrograde tracing. Neuroscience 5 12 (1980) 2093-2124
23. Hökfelt T., Herrera-Marschitz M., Seroogy K., Ju G., Staines W.A., Holets V., et al. Immunohistochemical studies on cholecystokinin (CCK)-immunoreactive neurons in the rat using sequence specific antisera and with special reference to the caudate nucleus and primary sensory neurons. J Chem Neuroanat 1 (1988) 11-52
24. Honda T., Wada E., Battey J.F., and Wank S.A. Differential gene expression of CCKA and CCKB receptors in the rat brain. Mol Cell Neurosci 4 (1993) 143-154
25. Jackson A., Tattersall D., Bentley G., Rycroft W., Bourson A., Hargreaves R., et al. An investigation into the discriminative stimulus and reinforcing properties of the CCKB-receptor antagonist, L-365,260 in rats. Neuropeptides 26 5 (1994) 343-353
26. Josselyn S.A., Franco V.P., and Vaccarino F.J. Devazepide, a CCKA receptor antagonist, impairs the acquisition of conditioned reward and conditioned activity. Psychopharmacology 123 2 (1996) 131-143
27. Josselyn S.A., Franco V.P., and Vaccarino F.J. PD-135158, a CCKB receptor antagonist, microinjected into the nucleus accumbens and the expression of conditioned rewarded behavior. Neurosci Lett 209 2 (1996) 85-88
28. Katsuura G., and Itoh S. Potentiation of beta-endorphin effects by proglumide in rats. Eur J Pharmacol 107 3 (1985) 363-366
29. Kim J.A., Pollak K.A., Hjelmstad G.O., and Fields H.L. A single cocaine exposure enhances both opioid reward and aversion through a ventral tegmental area-dependent mechanism. Proc Natl Acad Sci U S A 101 15 (2004) 5664-5669
30. Kramer M.S., Cutler N.R., Ballenger J.C., Patterson W.M., Mendels J., Chenault A., et al. A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder. Biol Psychiatry 37 7 (1995) 462-466
31. Ladurelle N., Keller G., Roques B.P., and Dauge V. Effects of CCK8 and of the CCKB-selective agonist BC264 on extracellular dopamine content in the anterior and posterior nucleus accumbens: a microdialysis study in freely moving rats. Brain Res 628 1-2 (1993) 254-262
32. Lanca A.J., De Cabo C., Arifuzzaman A.I., and Vaccarino F.J. Cholecystokinergic innervation of nucleus accumbens subregions. Peptides 19 5 (1998) 859-868
33. Lavigne G.J., Millington W.R., and Mueller G.P. The CCK-A and CCK-B receptor antagonists, devazepide and L-365, 260, enhance morphine antinociception only in non-acclimated rats exposed to a novel environment. Neuropeptides 21 2 (1992) 119-129
34. Lemaire M., Bohme G.A., Piot O., Roques B.P., and Blanchard J.C. CCK-A and CCK-B selective receptor agonists and antagonists modulate olfactory recognition in male rats. Psychopharmacology 115 4 (1994) 435-440
35. Lena I., Simon H., Roques B.P., and Dauge V. Opposing effects of two CCK(B) agonists on the retrieval phase of a two-trial memory task after systemic injection in the rat. Neuropharmacology 38 4 (1999) 543-553
36. Lena I., Dhotel H., Garbay C., and Dauge V. Involvement of D2 dopamine receptors in the opposing effects of two CCK-B agonists in a spatial recognition memory task: role of the anterior nucleus accumbens. Psychopharmacology (Berl) 153 2 (2001) 170-179
37. Li X.M., Hedlund P.B., and Fuxe K. Cholecystokinin octapeptide in vitro and ex vivo strongly modulates striatal dopamine D2 receptors in rat forebrain sections. Eur J Neurosci 7 5 (1995) 962-971
38. Lines C., Challenor J., and Traub M. Cholecystokinin and anxiety in normal volunteers: an investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype B antagonist L-365,260. Br J Clin Pharmacol 39 3 (1995) 235-242
39. Lodge D.J., and Lawrence A.J. Comparative analysis of the central CCK system in Fawn Hooded and Wistar Kyoto rats: extended localisation of CCK-A receptors throughout the rat brain using a novel radioligand. Regul Pept 99 2-3 (2001) 191-201
40. Lu L., Huang M., Ma L., and Li J. Different role of cholecystokinin CCK-A and CCK-B receptors in relapse to morphine dependence in rats. Behav Brain Res 120 1 (2001) 105-110
41. Lu L., Zhang B., Liu Z., and Zhang Z. Reactivation of cocaine conditioned place preference induced by stress is reversed by cholecystokinin-B receptors antagonist in rats. Brain Res 954 1 (2002) 132-140
42. Maidment N.T., Siddall B.J., Rudolph V.R., Erdelyi E., and Evans C.J. Dual determination of extracellular cholecystokinin and neurotensin fragments in rat forebrain: microdialysis combined with a sequential multiple antigen radioimmunoassay. Neuroscience 45 1 (1991) 81-93
43. Marshall F.H., Barnes S., Hughes J., Woodruff G.N., and Hunter J.C. Cholecystokinin modulates the release of dopamine from the anterior and posterior nucleus accumbens by two different mechanisms. J Neurochem 56 3 (1991) 917-922
44. McCleane G.J. A randomised, double blind, placebo controlled crossover study of the cholecystokinin 2 antagonist L-365, 260 as an adjunct to strong opioids in chronic human neuropathic pain. Neurosci Lett 338 2 (2003) 151-154
45. Mercer L.D., and Beart P.M. Immunolocalization of CCK1R in rat brain using a new anti-peptide antibody. Neurosci Lett 359 1-2 (2004) 109-113
46. Meyer D.K., Beinfeld M.C., Oertel W.H., and Brownstein M.J. Origin of the cholecystokinin containing fibers in the caudate-putamen. Science 215 (1982) 187-188
47. Morino P., Mascagni F., McDonald A., and Hökfelt T. Cholecystokinin corticostriatal pathway in the rat: evidence for bilateral origin from medial prefrontal cortical areas. Neuroscience 59 (1994) 939-952
48. Mueller D., and Stewart J. Cocaine-induced conditioned place preference: reinstatement by priming injections of cocaine after extinction. Behav Brain Res 115 1 (2000) 39-47
49. Mueller D., Perdikaris D., and Stewart J. Persistence and drug-induced reinstatement of a morphine-induced conditioned place preference. Behav Brain Res 136 2 (2002) 389-397
50. Murphy R.B., and Schuster D.I. Modulation of [3H]-dopamine binding by cholecystokinin octapeptide (CCK-8). Peptides 3 3 (1982) 539-543
51. Murphy M.G., Sytnik B., Kovacs T.O., Mertz H., Ewanik D., Shingo S., et al. The gastrin-receptor antagonist L-365, 260 inhibits stimulated acid secretion in humans. Clin Pharmacol Ther 54 5 (1993) 533-539
52. Nemeroff C.B., Osbahr A.J., Bissette G., Jahnke G., Lipton M.A., and Prange A.J. Cholecystokinin inhibits tail pinch-induced eating in rats. Science 200 4343 (1978) 793-794
53. Panerai A.E., Rovati L.C., Cocco E., Sacerdote P., and Mantegazza P. Dissociation of tolerance and dependence to morphine: a possible role for cholecystokinin. Brain Res 410 1 (1987) 52-60
54. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1998), Academic Press, San Diego
55. Phillips P.E., Hancock P.J., and Stamford J.A. Time window of autoreceptor-mediated inhibition of limbic and striatal dopamine release. Synapse 44 1 (2002) 15-22
56. Reynolds S.M., and Berridge K.C. Fear and feeding in the nucleus accumbens shell: rostrocaudal segregation of GABA-elicited defensive behavior versus eating behavior. J Neurosci 21 9 (2001) 3261-3270
57. Sebret A., Lena I., Crete D., Matsui T., Roques B.P., and Dauge V. Rat hippocampal neurons are critically involved in physiological improvement of memory processes induced by cholecystokinin-B receptor stimulation. J Neurosci 19 16 (1999) 7230-7237
58. Seroogy K.B., Dangaran K., Lim S., Haycock J.W., and Fallon J.H. Ventral mesencephalic neurons containing both cholecystokinin- and tyrosine hydroxylase-like immunoreactivities project to forebrain regions. J Comp Neurol 279 3 (1989) 397-414
59. Shlik J., Koszycki D., and Bradwejn J. Decrease in short-term memory function induced by CCK-4 in healthy volunteers. Peptides 19 6 (1998) 969-975
60. Singh L., Lewis A.S., Field M.J., Hughes J., and Woodruff G.N. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Proc Natl Acad Sci U S A 88 4 (1991) 1130-1133
61. Sramek J.J., Kramer M.S., Reines S.A., and Cutler N.R. Pilot study of a CCKB antagonist in patients with panic disorder: preliminary findings. Anxiety 1 3 (1994) 141-143
62. Tang J., Chou J., Iadarola M., Yang H.Y., and Costa E. Proglumide prevents and curtails acute tolerance to morphine in rats. Neuropharmacology 23 6 (1984) 715-718
63. Tanganelli S., Fuxe K., Antonelli T., O'Connor W.T., and Ferraro L. Cholecystokinin/dopamine/GABA interactions in the nucleus accumbens: biochemical and functional correlates. Peptides 22 8 (2001) 1229-1234
64. Tsutsumi T., Akiyoshi J., Isogawa K., Kohno Y., Hikichi T., and Nagayama H. Suppression of conditioned fear by administration of CCKB receptor antagonist PD135158. Neuropeptides 33 6 (1999) 483-486
65. Tzschentke T.M. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol 56 6 (1998) 613-672
66. Vaccarino F.J., and Vaccarino A.L. Antagonism of cholecystokinin function in the rostral and caudal nucleus accumbens: differential effects on brain stimulation reward. Neurosci Lett 97 1-2 (1989) 151-156
67. van Megen H.J., Westenberg H.G., and den Boer J.A. Effect of the cholecystokinin-B receptor antagonist L-365,260 on lactate-induced panic attacks in panic disorder patients. Biol Psychiatry 40 8 (1996) 804-806
68. Voigt M., Wang R.Y., and Westfall T.C. Cholecystokinin octapeptides alter the release of endogenous dopamine from the rat nucleus accumbens in vitro. J Pharmacol Exp Ther 237 1 (1986) 147-153
69. Wang R.Y., and Hu X.T. Does cholecystokinin potentiate dopamine action in the nucleus accumbens?. Brain Res 380 2 (1986) 363-367
70. Wang R.Y., White F.J., and Voigt M.M. Interactions of cholecystokinin and dopamine in the nucleus accumbens. Ann N Y Acad Sci 448 (1985) 352-360
71. Watkins L.R., Kinscheck I.B., and Mayer D.J. Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide. Science 224 4647 (1984) 395-396
72. White F.J., and Wang R.Y. Interactions of cholecystokinin octapeptide and dopamine on nucleus accumbens neurons. Brain Res 300 1 (1984) 161-166
73. Willis G.L., Hansky J., and Smith G.C. Central and peripheral proglumide administration and cholecystokinin-induced satiety. Regul Pept 15 1 (1986) 87-98
74. Yim C.C., and Mogenson G.J. Electrophysiological evidence of modulatory interaction between dopamine and cholecystokinin in the nucleus accumbens. Brain Res 541 1 (1991) 12-20
75. Yun I.A., Wakabayashi K.T., Fields H.L., and Nicola S.M. The ventral tegmental area is required for the behavioral and nucleus accumbens neuronal firing responses to incentive cues. J Neurosci 24 12 (2004) 2923-2933
76. You Z.B., Herrera-Marschitz M., Brodin E., Meana J.J., Morino P., Hökfelt T., et al. On the origin of striatal cholecystokinin release: studies with in vivo microdialysis. J Neurochem 62 (1994) 76-85
77. You Z.B., Tzschentke T.M., Brodin E., and Wise R.A. Electrical stimulation of the prefrontal cortex increases cholecystokinin, glutamate, and dopamine release in the nucleus accumbens: an in vivo microdialysis study in freely moving rats. J Neurosci 18 16 (1998) 6492-6500
78. Zajac J.M., Gully D., and Maffrand J.P. [3H]-SR 27897B: a selective probe for autoradiographic labelling of CCK-A receptors in the brain. J Recept Signal Transduct Res 16 1-2 (1996) 93-113